Published in Nervenarzt on May 01, 2005
Contemporary use and practice of electroconvulsive therapy worldwide. Brain Behav (2012) 1.34
LRRTM1 on chromosome 2p12 is a maternally suppressed gene that is associated paternally with handedness and schizophrenia. Mol Psychiatry (2007) 3.49
The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry (2006) 2.44
Copy number variations of chromosome 16p13.1 region associated with schizophrenia. Mol Psychiatry (2009) 2.29
Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry (2004) 1.63
Functional connectivity of the fusiform gyrus during a face-matching task in subjects with mild cognitive impairment. Brain (2006) 1.62
SNP and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene provide evidence for association with major depression. Mol Psychiatry (2004) 1.60
Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry (2004) 1.53
Combined action of the ACE D- and the G-protein beta3 T-allele in major depression: a possible link to cardiovascular disease? Mol Psychiatry (2002) 1.49
Results of a surveillance programme for patients at high risk of malignant melanoma using digital and conventional dermoscopy. Eur J Cancer Prev (2004) 1.41
Expanding the range of ZNF804A variants conferring risk of psychosis. Mol Psychiatry (2010) 1.41
Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry (2011) 1.40
[Core symptoms of depression. Effectiveness of antidepressant therapy]. Nervenarzt (2009) 1.40
Prolonged confusional state following electroconvulsive therapy--diagnostic clues from serial electroencephalography. Pharmacopsychiatry (2005) 1.39
Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry (1998) 1.38
Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry (2004) 1.31
Analysis of 10 independent samples provides evidence for association between schizophrenia and a SNP flanking fibroblast growth factor receptor 2. Mol Psychiatry (2008) 1.28
Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta Psychiatr Scand (2007) 1.22
Regional distribution of white matter hyperintensities in vascular dementia, Alzheimer's disease and healthy aging. Dement Geriatr Cogn Disord (2004) 1.22
Structural brain alterations in subjects at high-risk of psychosis: a voxel-based morphometric study. Schizophr Res (2008) 1.22
Prefrontal direct current stimulation modulates resting EEG and event-related potentials in healthy subjects: a standardized low resolution tomography (sLORETA) study. Neuroimage (2010) 1.22
Reduced gray matter brain volumes are associated with variants of the serotonin transporter gene in major depression. Mol Psychiatry (2008) 1.20
The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett (2001) 1.20
The role of dopamine for the pathophysiology of schizophrenia. Int Rev Psychiatry (2007) 1.18
Neuropsychological profile of adult patients with Niemann-Pick C1 (NPC1) mutations. J Inherit Metab Dis (2006) 1.15
Structural brain alterations at different stages of schizophrenia: a voxel-based morphometric study. Schizophr Res (2008) 1.13
Progesterone induces changes in sleep comparable to those of agonistic GABAA receptor modulators. Am J Physiol (1996) 1.11
Dizziness in an older community dwelling population: a multifactorial syndrome. J Nutr Health Aging (2009) 1.07
In vivo imaging of region and cell type specific neocortical neurodegeneration in Alzheimer's disease. Perspectives of MRI derived corpus callosum measurement for mapping disease progression and effects of therapy. Evidence from studies with MRI, EEG and PET. J Neural Transm (Vienna) (2002) 1.07
Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br J Dermatol (1999) 1.07
Association of anger-related traits with SNPs in the TPH gene. Mol Psychiatry (2002) 1.06
Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport (2000) 1.06
Co-expression of the 5-HT3B serotonin receptor subunit alters the biophysics of the 5-HT3 receptor. Biophys J (2003) 1.06
Polymorphisms in the angiotensin-converting enzyme gene are associated with unipolar depression, ACE activity and hypercortisolism. Mol Psychiatry (2006) 1.04
Heterodimerization between mineralocorticoid and glucocorticoid receptor: a new principle of glucocorticoid action in the CNS. Neuron (1994) 1.04
The SIMA-project: effects of 1 year cognitive and psychomotor training on cognitive abilities of the elderly. Behav Brain Res (1996) 1.03
Binding characteristics of the glucocorticoid receptor in peripheral blood lymphocytes in multiple sclerosis. J Neurol (1999) 1.03
Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry Suppl (2007) 1.02
Concentrations of 3 alpha-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biol Psychiatry (1999) 1.01
Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett (2001) 1.01
Identification and characterization of a 3',5'-cyclic adenosine monophosphate-responsive element in the human corticotropin-releasing hormone gene promoter. Mol Endocrinol (1992) 1.01
Regional pattern of hippocampus and corpus callosum atrophy in Alzheimer's disease in relation to dementia severity: evidence for early neocortical degeneration. Neurobiol Aging (2002) 1.01
Neuroactive steroids in affective disorders: target for novel antidepressant or anxiolytic drugs? Neuroscience (2011) 1.00
Progesterone-induced changes in sleep in male subjects. Am J Physiol (1997) 1.00
Allopregnanolone affects sleep in a benzodiazepine-like fashion. J Pharmacol Exp Ther (1997) 0.98
Cerebral differences in explicit and implicit emotional processing--an fMRI study. Neuropsychobiology (2007) 0.98
Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity. J Neural Transm (Vienna) (2003) 0.97
Resting state glucose utilization and the CERAD cognitive battery in patients with Alzheimer's disease. Neurobiol Aging (2006) 0.97
Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient. Pharmacopsychiatry (2002) 0.96
Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor. Mol Psychiatry (2003) 0.95
Neuroimaging genetics: new perspectives in research on major depression? Acta Psychiatr Scand (2008) 0.94
Translocator protein (18 kDa) as a target for novel anxiolytics with a favourable side-effect profile. J Neuroendocrinol (2012) 0.94
Association of a MAOA gene variant with generalized anxiety disorder, but not with panic disorder or major depression. Am J Med Genet B Neuropsychiatr Genet (2003) 0.94
The frailty syndrome in general practitioner care: a pilot study. Z Gerontol Geriatr (2010) 0.93
Amygdala reduction in patients with ADHD compared with major depression and healthy volunteers. Acta Psychiatr Scand (2009) 0.93
Molecular cloning, functional expression, and pharmacological characterization of 5-hydroxytryptamine3 receptor cDNA and its splice variants from guinea pig. Mol Pharmacol (1998) 0.93
Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone. Hum Psychopharmacol (2010) 0.93
Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner. Mol Psychiatry (2004) 0.93
Plexin B3 is genetically associated with verbal performance and white matter volume in human brain. Mol Psychiatry (2006) 0.92
Course and outcome of first-admitted patients with acute and transient psychotic disorders (ICD-10:F23). Focus on relapses and social adjustment. Eur Arch Psychiatry Clin Neurosci (2003) 0.92
Cognitive-behavioural theories of helplessness/hopelessness: valid models of depression? Eur Arch Psychiatry Clin Neurosci (2002) 0.92
Dysregulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of MS. Neurology (1999) 0.91
Neuroactive steroids as modulators of depression and anxiety. Neuroscience (2005) 0.91
Axonal regeneration and neuroinflammation: roles for the translocator protein 18 kDa. J Neuroendocrinol (2012) 0.91
Transcranial direct current stimulation in treatment resistant depression: a randomized double-blind, placebo-controlled study. Brain Stimul (2011) 0.91
Effects of fluoxetine, indomethacine and placebo on 3 alpha, 5 alpha tetrahydroprogesterone (THP) plasma levels in uncomplicated alcohol withdrawal. World J Biol Psychiatry (2000) 0.91
How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials? Eur Arch Psychiatry Clin Neurosci (2004) 0.91
Loudness dependence of primary auditory-cortex-evoked activity as predictor of therapeutic outcome to prophylactic lithium treatment in affective disorders--a retrospective study. Pharmacopsychiatry (2004) 0.90
EEG coherence reflects regional corpus callosum area in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2005) 0.90
Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology (2001) 0.89
Reduced subjective quality of life in persons at risk for psychosis. Acta Psychiatr Scand (2008) 0.89
Alpha-thujone reduces 5-HT3 receptor activity by an effect on the agonist-reduced desensitization. Neuropharmacology (2004) 0.89
Functional antagonism of gonadal steroids at the 5-hydroxytryptamine type 3 receptor. Mol Endocrinol (1998) 0.88
M129V variation in the prion protein may influence cognitive performance. Mol Psychiatry (2003) 0.88
Predictors for occasional and recurrent falls in community-dwelling older people. Z Gerontol Geriatr (2009) 0.87
European guidance: a project of the European Psychiatric Association. Eur Psychiatry (2011) 0.87
Predominant expression of tryptophan hydroxylase 1 mRNA in the pituitary: a postmortem study in human brain. Neuroscience (2009) 0.87
[Negative symptoms of schizophrenic patients from the perspective of psychiatrists, patients themselves and their relatives]. Nervenarzt (2003) 0.87
Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients. Eur Arch Psychiatry Clin Neurosci (2005) 0.87
Molecular and functional evidence for in vitro cytokine enhancement of human and murine target cell sensitivity to glucocorticoids. TNF-alpha priming increases glucocorticoid inhibition of TNF-alpha-induced cytotoxicity/apoptosis. J Clin Invest (1996) 0.87
Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression Scale. Acta Psychiatr Scand (2010) 0.86
Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study. Eur Psychiatry (2009) 0.86
Kinematic analysis of handwriting movements in patients with Alzheimer's disease, mild cognitive impairment, depression and healthy subjects. Dement Geriatr Cogn Disord (2003) 0.86
Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3alpha-hydroxysteroid dehydrogenase activity. Mol Psychiatry (2006) 0.85
Targeting glia cells: novel perspectives for the treatment of neuropsychiatric diseases. Curr Neuropharmacol (2013) 0.85
Fifteen-year follow-up of ICD-10 schizoaffective disorders compared with schizophrenia and affective disorders. Acta Psychiatr Scand (2004) 0.85
Placebo-controlled trials in major depression are necessary and ethically justifiable: how to improve the communication between researchers and ethical committees. Eur Arch Psychiatry Clin Neurosci (2004) 0.85
A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. J Nutr Health Aging (2012) 0.85
Fluoxetine decreases concentrations of 3 alpha, 5 alpha-tetrahydrodeoxycorticosterone (THDOC) in major depression. J Psychiatr Res (2000) 0.85
Cerebral changes and cognitive dysfunctions in medication-free schizophrenia - an fMRI study. J Psychiatr Res (2007) 0.84
The influence of subchronic administration of the neurosteroid allopregnanolone on sleep in the rat. Neuropsychopharmacology (2001) 0.84
5-HT1A receptor gene C -1019 G polymorphism and amygdala volume in borderline personality disorder. Genes Brain Behav (2008) 0.84
Effect of aripiprazole on cognition in the treatment of patients with schizophrenia. Pharmacopsychiatry (2009) 0.84
Flupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study. Eur Arch Psychiatry Clin Neurosci (2013) 0.84
Postmortem proteomic analysis in human amygdala of drug addicts: possible impact of tubulin on drug-abusing behavior. Eur Arch Psychiatry Clin Neurosci (2010) 0.83
GRIN1 locus may modify the susceptibility to seizures during alcohol withdrawal. Am J Med Genet B Neuropsychiatr Genet (2005) 0.83